SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

BIOCON

BSE: 532523 22 Aug 2025
Healthcare
₹ 358.4
Biocon Ltd. specializes in Pharmaceuticals within the Healthcare sector.

BIOCON - Share Price & Details

Market Cap
₹47,843
High /Low
406.0 / 291.0
Stock P/E
132.0
Book Value
₹180.0
Dividend Yield
0.14
ROCE
6.25
ROE
₹4.76
Face Value
5.0
PEG Ratio
12.6
EVEBITDA
₹18.0
Debt
18,362
CMP / FCF
49.6
Debt to equity
₹0.85
NP Ann
1,429
High price all time
488.0
Piotroski score
₹6.0
Graham Number
114.0
No. Eq. Shares
134.0
Net CF
₹2,004
Net profit
657
Price to book value
1.98
Interest Coverage
₹1.82
Low price all time
14.2
Industry PE
32.8
Reserves
₹21,044
Free Cash Flow
₹1,718

Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
Shyama Computronics and Servic1.480.930.670.005.3335.5
Triochem Products Ltd.,3.25-4.52NA-18.440
BIOCON LTD.5984.0-83.05371.0-0.0747,843132.0
GLAXOSMITHKLINE PHARMACEUTICAL8485.92047.08048.312.084696449.6
Narayana Hrudayalaya Limited9595.77873.719431.414.33776447.8

Peer Comparison Chart


About BIOCON

Biocon Ltd., with Security Code 532523, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Latest News

Biocon Q1 Profit Rises 7 Per Cent To Rs 2.9 Billion

(12 Aug 2025)
Biocon Ltd has posted a consolidated net profit of Rs 2.9 billion for the quarter ended June 2025, up 7 per cent from Rs 2.7 billion a year...
Read more →

Biocon Limited Just Missed Earnings - But Analysts Have Updated Their Models

(10 Aug 2025)
NSEI:BIOCON 1 Year Share Price vs Fair Value Explore Biocon's Fair Values from the Community and select yours There's...
Read more →

Biocon Faces Market Volatility Amid Broader Sector Declines and Bearish Trends

(09 Aug 2025)
Biocon Ltd. has faced a significant decline in its stock price, underperforming the broader market and sector trends.
Read more →

Biocon Biologics eyes global expansion with focus on insulin and GLP-1 therapies

(09 Aug 2025)
Biocon Biologics, a subsidiary of Biocon Ltd, is optimistic about long-term growth opportunities in both the insulin market and GLP-1...
Read more →

Biocon Biologics posts strong Q1 growth as North America, Europe deliver | Company Business News

(09 Aug 2025)
Biocon Biologics Ltd, the biosimilars unit of biopharmaceutical giant Biocon and its largest revenue driver, expects to accelerate growth...
Read more →

Biocon Q1 Net Profit Dips 95% to ₹31.4 Crore

(09 Aug 2025)
Biocon Ltd's Revenue from operations rose 14.8% year-on-year to ₹3942 crore. This is up from ₹3433 crore in Q1FY25.
Read more →

Company Updates